Search Results
Oct 23, 2025, 10:00 ET Pillar Biosciences to Showcase NGS Research Insights at 2025 AMP Meeting
"Rapid Detection of Actionable Biomarkers in Liquid Biopsy from Non-Small Cell Lung Cancer and Breast Cancer Using Targeted NGS-Based Assays," presented by Dr. Beatriz Bellosillo, PhD, Hospital del Mar and Ryan Demers, MSc, AstraZeneca
More news about: Pillar Biosciences, Inc.
Oct 23, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
in a Phase 3 IMPALA-2 pivotal clinical trial for the treatment of autoimmune pulmonary alveolar proteinosis ("aPAP"), a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Savara has consistently represented that, based on investments
More news about: Pomerantz LLP
Oct 23, 2025, 08:45 ET Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, olon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Oct 23, 2025, 08:38 ET Fractal Achieves AWS Generative AI Consulting Services Competency, Reinforcing its Leadership in AI Strategy and Implementation
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI research team is focused on foundational AI advancements, including knowledge-based foundational models,
More news about: Fractal Analytics Limited
Oct 23, 2025, 08:31 ET Immorta Bio Expands StemCellRevivify™ Platform to Harness Autologous "Younger" Mitochondria for Regeneration of Heart, Brain, and Liver
cells derived from the patient's own biology." Immorta Bio is preparing to initiate clinical trials of SenoVax™ in lung cancer, where tumors exploit senescent-cell mechanisms to shield themselves from immune attack. The Company also plans to advance StemCellRevivify™
More news about: Immorta Bio Inc.
Oct 23, 2025, 08:28 ET Fractal Achieves AWS Generative AI Consulting Services Competency, Reinforcing its Leadership in AI Strategy and Implementation
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI research team is focused on foundational AI advancements, including knowledge-based foundational models,
More news about: Fractal Analytics Limited
Oct 23, 2025, 08:24 ET Fractal Achieves AWS Generative AI Consulting Services Competency, Reinforcing its Leadership in AI Strategy and Implementation
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI research team is focused on foundational AI advancements, including knowledge-based foundational models,
More news about: Fractal Analytics Limited
Oct 23, 2025, 08:12 ET Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program
More news about: Genprex, Inc.
Oct 23, 2025, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Research Suggests that REQORSA May Be an Effective Treatment
More news about: Genprex, Inc.
Oct 23, 2025, 02:46 ET SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly,
More news about: THE ROSEN LAW FIRM, P. A.
Oct 22, 2025, 21:19 ET 대만, 아시아혁신자본 이니셔티브 출범…인공지능 허브 도약 포석
혁신•인공지능(AI) 분야의 아시아 허브로 구축하려는 전략적 프로그램이다. 펑진룽 ( Peng Jin-lung) FCC 위원장은 "이 이니셔티브는 대만의 장기 산업 발전을 주도하고 자본 시장의 글로벌 경쟁력을 강화하는 데 핵심적인 역할을 할 것"이라며 "이 플랫폼이 기업 성장과 변화를 지원하는 유연한 자금 조달 옵션을 제공하며, 대만이 아시아 최고의 자산 관리 허브가 되려는 목표
More news about: TWSE
Oct 22, 2025, 20:00 ET Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC
Baseline: All patients (N=24) had received ≥2 prior lines of therapy; 16/24 (66.7%) had lung metastases. Efficacy: Among the 23 evaluable patients, the combination therapy achieved:Objective
More news about: Harbour BioMed
Oct 22, 2025, 19:02 ET Innovations Stem Cell Center Named "Top Stem Cell Therapy Treatments Company 2025" by Life Sciences Review
and men's health (erectile dysfunction and Peyronie's disease). In one highlighted case, a patient with advanced COPD improved lung function from 28% to nearly 50% following ISCC therapy. Another patient with severe kidney disease avoided dialysis for over 20 years after treatment.
More news about: iMedstem LLC DBA Innovations Stem Cell Center
Oct 22, 2025, 18:40 ET Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
levels remaining above EC90 - critical for preventing viral rebound. Expert Systems' modeling predicts even higher concentrations in lung tissue versus plasma, enhancing antiviral exposure at the primary infection site.. Following successful completion of Phase 1
More news about: Expert Systems, Inc.
Oct 22, 2025, 18:06 ET Innovations Stem Cell Center Named "Top Stem Cell Therapy Treatments Company 2025" by Life Sciences Review
and men's health (erectile dysfunction and Peyronie's disease). In one highlighted case, a patient with advanced COPD improved lung function from 28% to nearly 50% following ISCC therapy. Another patient with severe kidney disease avoided dialysis for over 20 years after treatment.
More news about: iMedstem LLC DBA Innovations Stem Cell Center
Oct 22, 2025, 11:37 ET Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC
potential. The momentum behind the collaboration stems from the continued validation of iza-bren's efficacy. At the 2025 World Congress on Lung Cancer (WCLC), after Dr. Fang Wenfeng presented domestic clinical data, a physician from the prestigious MD Anderson Cancer Center in the U.S. approached
More news about: Biokin
Oct 22, 2025, 08:30 ET OncoHost Receives New York State Laboratory Permit, Expanding Availability of PROphetNSCLC® Precision Oncology Test
proprietary test, PROphetNSCLC®, has been commercially available since 2023 and supports oncologists treating patients with metastatic non-small cell lung cancer (mNSCLC). Using a single blood sample, the test analyzes thousands of plasma proteins to generate a personalized probability of clinical benefit
More news about: OncoHost
Oct 22, 2025, 06:04 ET American Lung Association Launches Campaign to Educate People Living With Lung Cancer and Lung Disease About Critical Vaccines
About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Oct 22, 2025, 02:00 ET ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
fosters strategic collaborations between industry and research institutes. This study is evaluating ACM-CpG in patients with advanced head and neck, lung, bladder, and kidney cancers and is designed to establish proof of mechanism to support global clinical development.
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
fosters strategic collaborations between industry and research institutes. This study is evaluating ACM-CpG in patients with advanced head and neck, lung, bladder, and kidney cancers and is designed to establish proof of mechanism to support global clinical development.
More news about: ACM Biolabs
Oct 22, 2025, 00:10 ET Taiwan Launches Asia Innovation Capital Initiative to Become AI Hub
instrumental in driving long-term industrial development and strengthening the global competitiveness of our capital markets," said FSC Chairman Peng Jin-lung. He emphasized that the platform offers flexible financing options to support corporate growth and transformation, while reinforcing Taiwan's ambition
More news about: TWSE
Oct 21, 2025, 20:25 ET Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
results presented at ASCO 2025 have demonstrated outstanding tumor responses and preliminary survival benefits of IBI363 across immunotherapy-resistant lung cancer, "cold tumors" such as acral and mucosal melanoma, and MSS colorectal cancer. IBI363 is now in registrational clinical development, including
More news about: Innovent Biologics
Oct 21, 2025, 19:30 ET PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV. Pneumonitis/Interstitial Lung Disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated with PADCEV. When PADCEV was given in combination with
More news about: Astellas Pharma Inc.
Oct 21, 2025, 17:31 ET Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight
representing a novel approach to the treatment of emphysema. Designed to address the underlying molecular mechanisms driving lung tissue damage and inflammation, SAR447537 aims to improve lung function and disease modification beyond current symptomatic treatments. The drug is currently active in Phase II for
More news about: DelveInsight Business Research, LLP
Oct 21, 2025, 09:20 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
company's intellectual property portfolio for its lead anthracycline candidate Annamycin being developed for acute myeloid leukemia and soft tissue sarcoma lung metastases. This Canadian patent complements previously issued U.S. and allowed European patents, with additional applications pending in major jurisdictions
More news about: Equity Insider